FGFR4 and metastatic neoplasm: Although these treatments are highly efficacious for most patients initially, long-term recurrences remain a major clinical problem for ILC.1,2 We have recently performed RNA-Sequencing on paired, metachronous primary, and metastatic tumors to the brain and bone.3,4 Here, we perform a subset analysis on the previously published clinical data, focusing only on ER+ patients treated with endocrine therapy prior to their recurrence, as well as report additional FGFR4 expression data from paired gastrointestinal (GI) and ovarian metastases.5